Postpartum hemorrhage
Conditions
Interventions
Control group:"1-dose regimen"of ergometrine maleate combined with oxytocin
Experimental group:A "2-dose regimen" of ergometrine maleate combined with oxytocin
Sponsors
Chongqing Health Center for Women and Children
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1.Age 20-40 years; 2.Singleton, term pregnancy (gestational age >=37 weeks); 3.Those with any of the following risk factors for postpartum hemorrhage: macrosomia (estimated weight >= 4000g), scarred uterus (history of cesarean section, uterine fibroid removal surgery), multiparity (number of deliveries >= 3 times), previous history of postpartum hemorrhage, or excessive uterine distension (excessive amniotic fluid, etc.); 4.Planned vaginal delivery or elective/emergency cesarean section; 5.subjects voluntarily participated and signed the written informed consent form;
Exclusion criteria
Exclusion criteria: 1) Known to be allergic to ergonovine maleate, oxytocin or any of the ergot alkaloids (e.g. bromocriptine, cabergoline); 2) Serious medical complications: severe heart disease (NYHA class III-IV), severe liver and kidney dysfunction; 3) Hypertension-related diseases: hypertensive disorders in pregnancy, chronic hypertension, preeclampsia, eclampsia; 4) History of glaucoma; 5) Sepsis or intrauterine infection; 6) Reproductive tract malformation, suspected or confirmed placenta accreta, placenta previa; 7) Prenatal hemoglobin =5cm or multiple >=2cm and >3 in number); 9) Postpartum use of drugs that may interact with ergonovine (strong inhibitors of CYP3A4 such as ketoconazole, erythromycin; other ergonovines; vasoconstrictors); 10) Participated in other drug clinical trials within the past 3 months; 11) Any other condition considered by the investigator to preclude participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative blood loss within 48 hours postpartum;Postpartum uterine involution rate;Incidence of postpartum hemorrhage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure; | — |
Countries
China
Contacts
Public ContactWang Lan
Chongqing Health Center for Women and Children
Outcome results
None listed